ImCheck HP

Exploring uncharted territories in immunomodulation
Butyrophilins & Gamma-delta T cells

ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.

Latest news


ImCheck Appoints Thomas Civik as Independent Chairman of the Board
Leadership & Corporate 
Read more
ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR
Science & Medicine 
Read more
ImCheck Therapeutics is proud to be part of the FT120 for the fourth year in a row!
Leadership & Corporate 
Read more

AACR Annual Meeting 2023

From  Apr 14, 2023  to  Apr 19, 2023 

Read more

Immuno-Oncology Summit Europe

From  Jun 20, 2023  to  Jun 22, 2023 

Read more

4th Gamma Delta T Therapies Summit

From  Jul 25, 2023  to  Jul 27, 2023 

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subscribe to receive our press releases and related news